Combination Therapy With Various Combinations of Aliskiren, Valsartan, and Hydrochlorothiazide in Hypertensive Patients Not Adequately Responsive to Hydrochlorothiazide Alone
Article first published online: 12 MAY 2009
© 2009 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 11, Issue 6, pages 324–332, June 2009
How to Cite
Geiger, H., Barranco, E., Gorostidi, M., Taylor, A., Zhang, X., Xiang, Z. and Zhang, J. (2009), Combination Therapy With Various Combinations of Aliskiren, Valsartan, and Hydrochlorothiazide in Hypertensive Patients Not Adequately Responsive to Hydrochlorothiazide Alone. The Journal of Clinical Hypertension, 11: 324–332. doi: 10.1111/j.1751-7176.2009.00114.x
- Issue published online: 9 JUN 2009
- Article first published online: 12 MAY 2009
- Manuscript received November 9, 2008; revised March 26, 2009; accepted April 2, 2009
This study investigated the efficacy and safety of several different multi-drug regimens including aliskiren, valsartan, and hydrochlorothiazide (HCTZ) in patients not adequately responsive to HCTZ as monotherapy. After 4 weeks of HCTZ treatment, patients (N=641) whose diastolic blood pressure (DBP) was ≥95 mm Hg were treated for 8 weeks with either aliskiren/valsartan/HCTZ, aliskiren/HCTZ, valsartan/HCTZ, or HCTZ alone. The primary efficacy variable was change in DBP from baseline to week 8 end point. The aliskiren/valsartan/HCTZ combination produced statistically significant additional reductions in systolic blood pressure (SBP)/DBP when compared with other groups. At week 8 end point, reductions in SBP/DBP in the respective treatment groups were 22/16, 15/11, 18/14, or 6/6 mm Hg. Aliskiren/valsartan/HCTZ produced significantly better blood pressure control (SBP/DBP <140/90 mm Hg; 66.7%) compared with other treatment groups (20.5%–48.7%). The safety profile of aliskiren/valsartan/HCTZ was similar to the 2-drug combinations, with a greater blood pressure–lowering effect in patients who had not responded to HCTZ monotherapy.